Stem cells and tissue engineering: an alternative treatment for craniofacial congenital malformations and articular degenerative diseases

Velasquillo, Cristina; Madrazo-Ibarra, Antonio; Gómez, Clarisa Villegas; Pérez-Dosal, Marcia; Melgarejo-Ramírez, Yaaziel; Ibarra, Clemente

doi:10.20517/2347-9264.2020.30

Cited by 3 publications

(4 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the production of autologous FVIII antibodies remained relatively low, as evidenced using the aPTT test, FVIII activity assay, and assessment of FVIII inhibitors (Figure 7). MSC-based therapies hold great promise for treating a range of diseases, including congenital defects [25], autoimmune diseases [26], cardiovascular diseases [27], and neurodegenerative diseases [28]. They have demonstrated effectiveness in tissue repair, organ regeneration, and various clinical applications [29].…”

Section: Discussionmentioning

confidence: 99%

In Utero Cell Treatment of Hemophilia A Mice via Human Amniotic Fluid Mesenchymal Stromal Cell Engraftment

Kao,

Yen,

Fan

et al. 2023

IJMS

View full text Add to dashboard Cite

Hemophilia is a genetic disorder linked to the sex chromosomes, resulting in impaired blood clotting due to insufficient intrinsic coagulation factors. There are approximately one million individuals worldwide with hemophilia, with hemophilia A being the most prevalent form. The current treatment for hemophilia A involves the administration of clotting factor VIII (FVIII) through regular and costly injections, which only provide temporary relief and pose inconveniences to patients. In utero transplantation (IUT) is an innovative method for addressing genetic disorders, taking advantage of the underdeveloped immune system of the fetus. This allows mesenchymal stromal cells to play a role in fetal development and potentially correct genetic abnormalities. The objective of this study was to assess the potential recovery of coagulation disorders in FVIII knockout hemophilia A mice through the administration of human amniotic fluid mesenchymal stromal cells (hAFMSCs) via IUT at the D14.5 fetal stage. The findings revealed that the transplanted human cells exhibited fusion with the recipient liver, with a ratio of approximately one human cell per 10,000 mouse cells and produced human FVIII protein in the livers of IUT-treated mice. Hemophilia A pups born to IUT recipients demonstrated substantial improvement in their coagulation issues from birth throughout the growth period of up to 12 weeks of age. Moreover, FVIII activity reached its peak at 6 weeks of age, while the levels of FVIII inhibitors remained relatively low during the 12-week testing period in mice with hemophilia. In conclusion, the results indicated that prenatal intrahepatic therapy using hAFMSCs has the potential to improve clotting issues in FVIII knockout mice, suggesting it as a potential clinical treatment for individuals with hemophilia A.

show abstract

Section: Discussionmentioning

confidence: 99%

In Utero Cell Treatment of Hemophilia A Mice via Human Amniotic Fluid Mesenchymal Stromal Cell Engraftment

Kao,

Yen,

Fan

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“… 5 , 40 Connective tissue progenitor cells (stem cells), despite being 0.01% to 0.02% of cells present in tibial marrow aspirate, 33 have important immunomodulatory effects, trophic abilities, and chondrocyte differentiation potential. 22 , 37 , 38 These progenitor cells are primarily secretory cells capable of stimulating preexisting chondrocytes in repairing and regenerating articular cartilage. 4 , 28 , 34 Because of these important cells, BMA has been previously suggested to be a more appropriate biologic treatment for OA.…”

Section: Discussionmentioning

confidence: 99%

Carboplasty, a Simple Tibial Marrow Technique for Knee Osteoarthritis: A Placebo-Controlled Randomized Trial

Madrazo-Ibarra

Barve

Carroll

et al. 2022

Orthopaedic Journal of Sports Medicine

View full text Add to dashboard Cite

Background: Carboplasty is a new minimally invasive technique for knee osteoarthritis (OA) that consists of injecting tibial marrow aspirate into the bone-cartilage interface as well as intra-articularly. Purpose: To compare the clinical and imaging outcomes, as well as the safety, of carboplasty for symptomatic knee OA in a placebo-controlled trial. Study Design: Randomized controlled trial; Level of evidence, 1. Methods: The authors conducted a randomized controlled trial to compare carboplasty with placebo for the treatment of symptomatic knee OA. Patients who had failed medical treatment and had bone edema on magnetic resonance imaging (MRI) were randomized in a 1:1 ratio to carboplasty or placebo. The primary outcome of the study was the Numeric Pain Rating Scale (NPRS) for the knee at 1 year (scores range from 0 to 10, with a higher score indicating worse pain). Secondary outcomes were the Knee injury and Osteoarthritis Outcome Score (KOOS), treatment responder rate (based on achieving the minimal clinically important difference of the NPRS), MRI bone edema reduction, and treatment safety. Results: In total, 50 patients (25 carboplasty vs 25 placebo) were enrolled and followed up with for an average of 18 months (range, 14-24 months). The average NPRS at baseline decreased from 7.1 ± 0.9 to 2.9 ± 2.1 ( P < .001) at 1 year in the carboplasty group and from 7.7 ± 0.9 to 4.9 ± 2.2 ( P < .001) in the placebo group. On average, patients after carboplasty improved 60% from their initial NPRS, and patients after placebo improved 37% ( P = .003). Patients had a statistically significantly greater improvement from baseline in all KOOS subscales in the carboplasty group compared with the placebo group ( P < .001). The responder rates were 96% for carboplasty and 76% for placebo ( P = .098). Bone edema was reduced in 72% of patients in the carboplasty group and 44% of patients in the placebo group ( P = .045). Neither group had adverse events related to treatment. Conclusion: Carboplasty resulted in greater pain reduction, a significantly greater improvement in all KOOS subscales, and a similar safety profile compared with placebo in patients with symptomatic knee OA and bone edema. Registration: ISRCTN69838191 (ISRCT Registry).

show abstract

“…Mesenchymal stem cells (MSCs) are used as an unspecialized source of stem cells for tissue regeneration due to their chondrogenic differentiation capacity and trophic factor secretion [ 4 – 8 ]. These cells could be derived from various sources, such as bone marrow, adipose tissue, fetal membranes, synovial membrane, peripheral blood, tendons, and cartilages [ 9 – 11 ].…”

Section: Introductionmentioning

confidence: 99%

“…MSCs should express certain cell surface markers, such as CD73, CD90, and CD105, when adherent to plastic under normal tissue culture conditions, while it lacks expression of other markers, including CD45, CD34, CD14, CD11b, CD79∝, and CD19, because here was no significant surface marker for MSC identification [ 4 , 11 – 14 ].…”

Section: Introductionmentioning

confidence: 99%

Auricular cartilage regeneration using different types of mesenchymal stem cells in rabbits

et al. 2022

View full text Add to dashboard Cite

Background Cartilaginous disorders comprise a wide range of diseases that affect normal joint movement, ear and nose shape; and they have great social and economic impact. Mesenchymal stem cells (MSCs) provide a promising regeneration alternative for treatment of degenerative cartilaginous disorders. This study aimed to compare therapeutic potential of different types of laser activated MSCs to promote auricular cartilage regeneration. Twelve adult rabbit allocated equally in four groups, all animals received a surgical mid auricular cartilage defect in one ear; Group I (Positive control) injected sub-perichondrially with phosphate-buffered saline (PBS), Group II (ADMSC-transplanted group) injected adipose-derived MSCs (ADMSCs), Group III (BMMSCs-transplanted group) received bone marrow-derived MSCs (BMMSCs), and Group IV (EMSC-transplanted group) received ear MSCs (EMSCs) in the defected ear. The auricular defect was analyzed morphologically, histopathologically and immunohistochemically after 4 weeks. In addition, a quantitative real-time polymerase chain reaction was used to examine expression of the collagen type II (Col II) and aggrecan as cartilage growth factors. Results The auricles of all treatments appeared completely healed with smooth surfaces and similar tissue color. Histopathologically, defective areas of control positive group, ADMSCs and EMSCs treated groups experienced a small area of immature cartilage. While BMMSCs treated group exhibited typical features of new cartilage formation with mature chondrocytes inside their lacunae and dense extracellular matrix (ECM). In addition, BMMSC treated group showed a positive reaction to Masson’s trichrome and orcein stains. In contrary, control positive, ADMSC and EMSC groups revealed faint staining with Masson’s trichrome and Orcein. Immunohistochemically, there was an intense positive S100 expression in BMMSCs (with a significant increase of area percentage + 21.89 (P < 0.05), a moderate reaction in EMSCs (with an area percentage + 17.97, and a mild reaction in the control group and ADMSCs (area percentages + 8.02 and + 11.37, respectively). The expression of relative col II and aggrecan was substantially highest in BMMSCs (± 0.91 and ± 0.89, respectively). While, Control positive, ADMSCs and EMSCs groups recorded (± 0.41: ± 0.21, ± 0.6: ± 0.44, ± 0.61: ± 0.63) respectively. Conclusion BMMSCs showed the highest chondrogenic potential compared to ADMSCs and EMSCs and should be considered the first choice in treatment of cartilaginous degenerative disorders.

show abstract

Stem cells and tissue engineering: an alternative treatment for craniofacial congenital malformations and articular degenerative diseases

Cited by 3 publications

References 120 publications

In Utero Cell Treatment of Hemophilia A Mice via Human Amniotic Fluid Mesenchymal Stromal Cell Engraftment

In Utero Cell Treatment of Hemophilia A Mice via Human Amniotic Fluid Mesenchymal Stromal Cell Engraftment

Carboplasty, a Simple Tibial Marrow Technique for Knee Osteoarthritis: A Placebo-Controlled Randomized Trial

Auricular cartilage regeneration using different types of mesenchymal stem cells in rabbits

Contact Info

Product

Resources

About